Bcr-Abl inhibitor AT9283, Purity ≥98%

Synonym: AT9283; 896466-04-9; 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea; AT-9283; AT 9283; AT-9283 free base; Bcr-Abl inhibitor

MDL: MFCD12031513
CAS Number: 896466-04-9
Compound CID: 135398495

Product Size

5 mg; 10 mg; 25 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

AT9283, soluble in DMSO and ethanol and insoluble in water, specifically inhibits the activity of the Bcr-Abl tyrosine kinase. It targets Aurora A, JAK2, Abl (Q252H), Abl1 (T315I), AuroraB, DRAK1, FGFR1, FGFR1 (V561M), FGFR2, FGFR2 (N549H), and FGFR3.

Molecular Weight

381.4

Molecular Formula

C₁₉H₂₃N₇O₂

Targets

Aurora A: 3.0 nM; JAK2: 1.2 nM; Abl (Q252H): 10-30 nM; Abl1 (T315I): 4 nM; AuroraB: 3.0 nM; DRAK1: 10-30 nM; FGFR1: 10-30 nM; FGFR1 (V561M): 10-30 nM; FGFR2: 1-10 nM; FGFR2 (N549H): 10-30 nM; FGFR3: 10-30 nM

Form

Lyophilized powder

Purity

≥98%

Solubility

DMSO: 68 mg/mL (178.28 mM); Water: Insoluble; Ethanol: 34 mg/mL (89.13 mM)

Identity

Confirmed by NMR/HPLC/MS.

Applications

AT9283 serves as a research compound to investigate inhibition of multiple kinases including JAK2, with applications in cancer therapy.